Login to Your Account



Competition for MS Therapies Heats Up

Teva's MS Drug Nails Primary Endpoints – and Then Some

By Marie Powers


Friday, December 10, 2010
Teva Pharmaceutical Industries Ltd. has reported that its oral laquinimod for relapsing-remitting multiple sclerosis (RRMS) hit the primary endpoint in its two-year Phase III ALLEGRO study, demonstrating significant reduction in annualized relapse rate compared to placebo.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription